ANALYSIS OF NASAL SECRETIONS DURING EXPERIMENTAL RHINOVIRUS UPPER RESPIRATORY-INFECTIONS

被引:87
作者
IGARASHI, Y
SKONER, DP
DOYLE, WJ
WHITE, MV
FIREMAN, P
KALINER, MA
机构
[1] NIAID,CLIN INVEST LAB,ALLERG DIS SECT,BETHESDA,MD 20892
[2] UNIV PITTSBURGH,SCH MED,CHILDRENS HOSP PITTSBURGH,DEPT OTOLARYNGOL,PITTSBURGH,PA 15261
[3] UNIV PITTSBURGH,SCH MED,CHILDRENS HOSP PITTSBURGH,DEPT ALLERGY IMMUNOL & RHEUMATOL,PITTSBURGH,PA 15261
关键词
ALLERGIC RHINITIS; NASAL SECRETION; GLANDULAR SECRETION; RHINOVIRUS; VASCULAR PERMEABILITY;
D O I
10.1016/0091-6749(93)90016-9
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
Background: To determine the underlying mechanisms for rhinovirus-induced nasal secretions, nasal lavage fluids were analyzed during experimental rhinovirus infections. Methods: Twenty patients with allergic rhinitis and 18 nonallergic control subjects were inoculated with rhinovirus type 39. Nasal lavage was performed before and on days 2 through 7 after viral inoculation, and the lavage fluids were assayed for proteins and mast cell mediators. Results: The secretion of total protein and both plasma proteins (albumin and IgG) and glandular proteins (lactoferrin, lysozyme, and secretory IgA) increased after rhinovirus inoculation. Analysis of the specific protein constituents revealed that nasal secretions during the initial response to the rhinovirus infection were predominantly due to increased vascular permeability. Allergic subjects tended to have fewer symptoms and more vascular permeability than control subjects, and increased histamine secretion after rhinovirus inoculation was more frequently seen in the allergy group. Conclusion: Nasal secretions found early in the course of a viral upper respiratory infection are due to increased vascular permeability, whereas glandular secretions predominate later in the infection.
引用
收藏
页码:722 / 731
页数:10
相关论文
共 53 条
[1]   GASTRIN-RELEASING PEPTIDE IN HUMAN NASAL-MUCOSA [J].
BARANIUK, JN ;
LUNDGREN, JD ;
GOFF, J ;
PEDEN, D ;
MERIDA, M ;
SHELHAMER, J ;
KALINER, M .
JOURNAL OF CLINICAL INVESTIGATION, 1990, 85 (04) :998-1005
[2]   SUBSTANCE-P AND NEUROKININ-A IN HUMAN NASAL-MUCOSA [J].
BARANIUK, JN ;
LUNDGREN, JD ;
OKAYAMA, M ;
GOFF, J ;
MULLOL, J ;
MERIDA, M ;
SHELHAMER, JH ;
KALINER, MA .
AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY, 1991, 4 (03) :228-236
[3]   BRADYKININ AND RESPIRATORY MUCOUS-MEMBRANES - ANALYSIS OF BRADYKININ BINDING-SITE DISTRIBUTION AND SECRETORY RESPONSES INVITRO AND INVIVO [J].
BARANIUK, JN ;
LUNDGREN, JD ;
MIZOGUCHI, H ;
PEDEN, D ;
GAWIN, A ;
MERIDA, M ;
SHELHAMER, JH ;
KALINER, MA .
AMERICAN REVIEW OF RESPIRATORY DISEASE, 1990, 141 (03) :706-714
[4]  
BISSET GW, 1962, BRIT J PHARM CHEMOTH, V19, P168
[5]  
BUTLER WT, 1970, J IMMUNOL, V105, P584
[6]   MECHANISMS OF MEDIATOR RELEASE FROM HUMAN SKIN MAST-CELLS UPON STIMULATION BY THE BRADYKININ ANALOG, [DARG0-HYP3-DPHE7]BRADYKININ [J].
COHAN, VL ;
MACGLASHAN, DW ;
WARNER, JA ;
LICHTENSTEIN, LM ;
PROUD, D .
BIOCHEMICAL PHARMACOLOGY, 1991, 41 (02) :293-300
[7]  
DOUGLAS RG, 1968, ANTIMICROBIAL AGENTS, P340
[8]   RHINOVIRUS-39 INFECTION IN ALLERGIC AND NONALLERGIC SUBJECTS [J].
DOYLE, WJ ;
SKONER, DP ;
FIREMAN, P ;
SEROKY, JT ;
GREEN, I ;
RUBEN, F ;
KARDATZKE, DR ;
GWALTNEY, JM .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1992, 89 (05) :968-978
[9]  
DOYLE WJ, 1992, J ALLERGY CLIN IMMUN, V89, P9688
[10]  
EGGLESTON PA, 1984, ACTA OTOLARYNGOL S S, V413, P25